

Attorney Docket No.: 4394.214-US

PATENT

RECEIVED

MAR 06 2001

TECH CENTER 1600/2900

In re Application of: Svendsen et al.

Serial No.: 09/325,603

Group Art Unit: 1652

Filed: June 3, 1999

Examiner: E. Slobodyansky

Confirmation No: 3011

For:  $\alpha$ -Amylase Variants

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Amendment Fee Transmittal (in duplicate)
2. Amendment and Marked Up Version pursuant to 37 C.F.R. 1.21
3. Notice of Appeal (in duplicate)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on February 28, 2001.

Kelley O'Patry  
(name of person mailing paper)

  
(signature of person mailing paper)

#16  
Dmt  
343-01

Attorney Docket No.: 4394.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Serial No.: 09/325,603

Filed: June 3, 1999

Confirmation No: 3011

For: -Amylase Variants



Group Art Unit: 1652

Examiner: E. Slobodyansky

RECEIVED

MAR 0 2001

TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed August 30, 2000.

It is respectfully requested that the time for response to the Office Action dated August 30, 2000 be extended for a period of 3 months from November 30, 2000 to February 28, 2001. The required fee for the extension is estimated to be \$890.00.

The fee for claims has been calculated as shown below:

Total:  $2 - 20 = 0 \times 18 = \$0$


Independent:  $2 - 3 = 0 \times 80 = \$0$

No additional claims fee is required.

Please charge the required extension, estimated to be \$890.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 28, 2001

  
Jason I. Garbell, Reg. No. 44, 116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

03/05/2001 GTEFFERA 00000056 501701 09325603

01 FC:117 890.00 CH